Clinical Study ResultsThe prior P2a study reported positive results for moderate-to-severe hemorrhagic cystitis patients treated with LP-10, with improvements in various urinary symptoms.
Market OpportunityLarge market opportunity for LP-10 due to lack of approved treatments for hemorrhagic cystitis, with positive P2 results validating the improved safety and delivery.
Regulatory SupportLP-410 granted orphan drug designation for oral GvHD, indicating a supportive regulatory environment and potential market exclusivity benefits.